Karyopharm Therapeutics
KPTI | NASDAQ
$0.11
-$0.55 (-83.38%)
At close: Nov 2, 2026, 4:00 PM ET
Karyopharm Therapeutics Company Profile
Company profile explainedCompany Profile
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Richard A. Paulson | President, Chief Executive Officer & Director |
| Lori A. Macomber | Executive Vice President, Chief Financial Officer & Treasurer |
| Michael J. Mano | Executive VP, Chief Legal Officer & Secretary |
| Brendan Twohig Strong | Senior Vice President of Investor Relations |
| James Accumanno | Chief Compliance Officer |
| Kristin Abate | Vice President, Chief Accounting Officer & Assistant Treasurer |
| Lisa DiPaolo | Executive Vice President & Chief Human Resource Officer |
| Reshma Rangwala | Executive Vice President, Chief Medical Officer & Head of Research |
| Sharon Shacham | Co-Founder & Chairman of Scientific Advisory Board |
| Stuart Poulton | Executive Vice President & Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 4 | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 02, 2026 | 4 | Filing |
| Sep 25, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 25, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 8-K | Current Report |
Karyopharm Therapeutics
| Country | United States |
| IPO Date | Nov 6, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 228 |
| CEO | Richard A. Paulson |
Contact Details
85 Wells Avenue Newton,
Massachusetts 02459-3298 United States
Stock Details
| Ticker Symbol | KPTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001503802 |
| CUSIP Number | 48576U205 |
| ISIN Number | US48576U2050 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove KPTI